Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last A$0.03 AUD
Change Today -0.001 / -3.33%
Volume 344.0K
As of 11:42 PM 06/30/15 All times are local (Market data is delayed by at least 15 minutes).

cellmid ltd (CDY) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/2/14 - A$0.04
52 Week Low
04/8/15 - A$0.02
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CELLMID LTD (CDY)

Related News

No related news articles were found.

cellmid ltd (CDY) Related Businessweek News

No Related Businessweek News Found

cellmid ltd (CDY) Details

Cellmid Limited develops and commercializes diagnostic and therapeutic products for cancer and various chronic inflammatory conditions in Australia. It offers MK ELISA, a sandwich enzyme immunoassay in a 96 well plate format for measuring midkine levels in human serum samples. The company’s pipeline of products include CAB102, a humanized monoclonal antibody for use in solid tumors; CAB101, a monoclonal antibody for the treatment of inflammatory and autoimmune diseases; CMK103, a recombinant for use in cardiac ischemia. It also develops and sells FGF-5 inhibitor, an over the counter treatments to alleviate excessive and abnormal hair loss and reestablish the natural hair growth cycle. The company is based in Sydney, Australia.

cellmid ltd (CDY) Top Compensated Officers

Chief Executive Officer, Managing Director an...
Total Annual Compensation: A$434.5K
Compensation as of Fiscal Year 2014.

cellmid ltd (CDY) Key Developments

Cellmid Limited Signs Hair Growth Supply Agreement with Maywufa Company Ltd

Cellmid Limited announced that the company has made its first private label entry into the $5 billion global hair growth and anti-aging hair care market with the signing of an agreement with Maywufa Company Ltd. This combines Maywufa’s established Taiwanese brand name and extensive distribution channels with the company's scientifically and clinically validated FGF5 inhibitor hair growth products. It acts as exclusive distributor or agent to several large pharmaceutical and cosmetics companies representing major international brands as well as manufacturing and marketing products under its own Maywufa brand. Under the agreement Cellmid will manufacture and sell to Maywufa FGF5 inhibitor hair growth products under their brand. Selling its FGF5 inhibitor products through private label supply agreements is a key expansion strategy for Cellmid which is currently in negotiations with a number of international brand owners to grow this business further in the future.

Cellmid Limited Announces Board Changes

Cellmid Limited announced that Messrs Graeme Kaufman and Martin Rogers have resigned and will leave the Board effective on 30 June 2015. Mr. Bruce Gordon will be appointed as non-executive director to the Board, effective 1 July 2015. Mr. Kaufman was appointed to the Board of Cellmid on 27 August 2012 and Mr. Rogers was appointed to the Board of Cellmid on 19 September 2012. The company appointed Mr. Bruce Gordon, who will be joining the Board on 1 July 2015, has over 25 years of audit and finance experience in industries such as retail, healthcare, resources and manufacturing. After a distinguished career as Senior Audit Partner, in his most recent role he was Partner in Charge of BDO Australia's National Corporate Finance Team. He brings considerable international corporate finance experience to his role as non-executive director of Cellmid, in addition to his deep knowledge of the Company.

Cellmid Limited Presents at Asia Biotech Invest 2015, May-20-2015 10:00 AM

Cellmid Limited Presents at Asia Biotech Invest 2015, May-20-2015 10:00 AM. Venue: Sheraton Hotel & Towers, Hong Kong. Speakers: Maria Halasz, Chief Executive Officer, Managing Director and Executive Director.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CDY:AU A$0.03 AUD -0.001

CDY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CDY.
View Industry Companies

Industry Analysis


Industry Average

Valuation CDY Industry Range
No financial data is available for CDY.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CELLMID LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at